Meclofenoxate

Meclofenoxate (INN, BAN; brand name Lucidril, also known as centrophenoxine) is a cholinergic nootropic used as a dietary supplement.^[2][3][4] It is an ester of dimethylethanolamine (DMAE) and 4-chlorophenoxyacetic acid (pCPA).

Meclofenoxate

Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	N06BX01 (WHO)
Legal status
Legal status	BR: Class C1 (Other controlled substances)[1] US: Not FDA approved In general: ℞ (Prescription only)
Identifiers
IUPAC name 2-Dimethylaminoethyl (4-chlorophenoxy)acetate
CAS Number	51-68-3 Y
PubChem CID	4039
ChemSpider	3899 N
UNII	C76QQ2I0RG
KEGG	D00993 Y
CompTox Dashboard (EPA)	DTXSID9046940
ECHA InfoCard	100.000.107
Chemical and physical data
Formula	C12H16ClNO3
Molar mass	257.71 g·mol−1
3D model (JSmol)	Interactive image
SMILES Clc1ccc(cc1)OCC(=O)OCCN(C)C
InChI InChI=1S/C12H16ClNO3/c1-14(2)7-8-16-12(15)9-17-11-5-3-10(13)4-6-11/h3-6H,7-9H2,1-2H3 N Key:XZTYGFHCIAKPGJ-UHFFFAOYSA-N N
NY (what is this?)  (verify)

In elderly patients, meclofenoxate has been shown to improve performance on certain memory tests.^[5] Meclofenoxate also increases cellular membrane phospholipids.^{[citation needed]} It is sold in Japan and some European countries, such as Germany, Hungary, and Austria, as a prescription drug.

Side effects

Meclofenoxate is considered to be safe and high in tolerability. However, possible side effects may include, rarely, insomnia, dizziness, restlessness, muscle tremor, depression, nausea, muscle tension, and headache; these side effects may be due to overdosage and may indicate the need for the dosage to be reduced.

Research

Meclofenoxate, as well as DMAE, have been found to increase the lifespans of mice by 26.5%.^[6][7]

Brand names

In addition to Lucidril, meclofenoxate has also been marketed under the brand names Amipolen, Analux, Brenal, Cellative, Centrophenoxin, Cerebron, Cerutil, Closete, Helfergin, Lucidryl, Lutiaron, Marucotol, Proserout, Proseryl, and Ropoxyl.^[8] In the US, meclofenoxate is sold as a dietary supplement, although it is an unapproved drug.^[4]

See also

• Medicine portal

• Adafenoxate
• Cyprodenate
• ISRIB

References

1. Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
2. Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 758–. ISBN 978-1-4757-2085-3.
3. Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 636–. ISBN 978-3-88763-075-1.
4. Cohen PA, Avula B, Khan I (October 2022). "The unapproved drug centrophenoxine (meclofenoxate) in cognitive enhancement dietary supplements". Clinical Toxicology. 60 (10): 1156–1158. doi:10.1080/15563650.2022.2109485. PMID 35959800. S2CID 251516603.
5. Marcer D, Hopkins SM (May 1977). "The differential effects of meclofenoxate on memory loss in the elderly". Age and Ageing. 6 (2): 123–31. doi:10.1093/ageing/6.2.123. PMID 329662.
6. Donaldson T (1 January 2003). "A Brief History of Anti-aging Drugs". In Klatz R, Goldman B (eds.). The Science of Anti-aging Medicine. American Academy of Anti-Aging Med. pp. 66–. ISBN 978-0-9668937-3-1.
7. Hothschild R (August 1973). "Effect of dimethylamnioethyl p-chlorophenoxyacetate on the life span of male Swiss Webster Albino mice". Experimental Gerontology. 8 (4): 177–183. doi:10.1016/0531-5565(73)90024-7. PMID 4147092.
8. Zhou Y (22 October 2013). Drugs in Psychiatric Practice. Elsevier. ISBN 978-1-4831-9193-5.